Alliance for Clinical Trials in Oncology
Date Friday, May 11, 2018
Loews Hotel Chicago O'Hare
Room: Guggenheim 1
Time 8:00 am – 10:00 am

The Value of Genetic Ancestry in Understanding Cancer Health Disparities
Health Disparities Education Session Agenda

Meeting available by teleconference: Dial 800-501-8979 Access Code: 7029171

Chair:	Electra Paskett, PhD
Vice-Chairs:	Judith Kaur, MD and Gary Unzeitig, MD
Education Session Organizer:	Coleen Crespo, MIS

Time	Description/Title	Presenter
8:00	Welcome and Introductions Pre-test	Coleen Crespo, MIS
	Scientific Speakers	
8:10	The Value of Ancestral Information Markers	Tim Rebbeck, PhD
8:30	The Importance of Self-Reported Race and Ethnicity	Beti Thompson, PhD
8:50	Genetic Testing and Counseling in Minority Populations	Heather Hampel, LGC
9:10	Use of Genetic Testing on Tumors to Determine Treatment	Alice P. Chen, MD
9:30	**Panel Discussion and Audience Participation** Scientific Presenters: Tim Rebbeck, PhD; Beti Thompson, PhD; Heather Hampel, LGC; Alice P. Chen, MD Patient Advocates: Coleen Crespo, MIS, Phyllis Nassi, MSW, Ivis Sampayo	Moderator: Coleen Crespo, MIS
9:50	Post-test and Wrap Up	Coleen Crespo, MIS
10:00	Adjourn	

The Value of Genetic Ancestry in Understanding Cancer Health Disparities
Presenter Objectives

Tim Rebbeck, PhD
Harvard University, Chan School of Public Health
- Objective 1: Explain how genetic ancestry is defined and measured
- Objective 2: Discuss how population and evolutionary genetic events result in observed genetic ancestry patterns
- Objective 3: Demonstrate how genetic ancestry may be correlated with disease susceptibility

Beti Thompson, PhD
Fred Hutchinson Cancer Center
- Objective 1: Define and differentiate between race, ethnicity, and ancestry
- Objective 2: Define characteristics of an admixed individual
- Objective 3: Describe the implications of using self-reported race and ethnicity

Heather Hampel, **LGC**
Ohio State University, Comprehensive Cancer Center
- Objective 1: Identify issues with access to cancer genetics services among minority patients
- Objective 2: Discuss how less testing among minority patients can lead to less informative results
- Objective 3: Evaluate ways to improve access to cancer genetics services

Alice P. Chen, MD
National Cancer Institute, NCI-MATCH Trial
- Objective 1: Describe the principles of precision medicine
- Objective 2: Evaluate the selection of treatment based on genetic testing
- Objective 3: Explain the ethical issues of setting up a precision medicine trial